Bipolar Disorder trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Bipolar Disorder. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month3 studies across 3 companies, in the next 180 days.
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ALKS | Alkermes, Inc. | Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderNCT05303064Change from baseline in body mass index (BMI) Zscore at week 12 | Phase 3 | Recruiting | Sep 2026 | ≤ 41 d | 2026-08-14 |
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ALZN | Alzamend Neuro, Inc. | A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I DisorderNCT07540338To evaluate differences in brain and/or brain structure lithium PK relative to plasma PK for AL001 capsule compared to a lithium carbonate capsule. | Phase 1/2 | Recruiting | Dec 2026 | ≤ 133 d | 2026-07-28 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NBIX | Neurocrine Biosciences | A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) InhibitorNCT07105111Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score (AIMS 1-7) at Week 24 | Phase 4 | Recruiting | Jan 2027 | ≤ 164 d | 2026-06-16 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Bipolar Disorder
most recently updated first137 studies match. Showing the first 100 of 137 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALKS | Alkermes, Inc. | $8.3B | Long-term Safety Extension Study of OLZ/SAM in Pediatric SubjectsNCT04987229Incidence of adverse events | Phase 3 | Enrolling by invitation | Drug: OLZ/SAM | Bipolar I Disorder, Schizophrenia | 236 | 2021-10-22 | Sep 2027 | ≤ 406 d | 2026-08-14 |
| ALKS | Alkermes, Inc. | $8.3B | Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderNCT05303064Change from baseline in body mass index (BMI) Zscore at week 12 | Phase 3 | Recruiting | Drug: OLZ/SAM, Olanzapine | Schizophrenia, Bipolar I Disorder | 220 | 2022-06-30 | Sep 2026 | ≤ 41 d | 2026-08-14 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II DisorderNCT06696755Change from Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) total score | Phase 2 | Recruiting | Drug: Icalcaprant, Placebo for Icalcaprant | Bipolar I Disorder, Bipolar II Disorder | 195 | 2026-02-03 | Nov 2027 | ≤ 467 d | 2026-08-14 |
| BTAI | BioXcel Therapeutics Inc | $25M | Dexmedetomidine in the Treatment of Agitation Associated With Bipolar DisorderNCT04276883results2023-09-11Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score | Phase 3 | Completed | Drug: Sublingual film containing Dexmedetomidine (BXCL501), Placebo Film | Agitation Associated With Bipolar Disorder, Agitation,Psychomotor, Bipolar Disorder | 380 | 2020-02-24 | 2020-05-21actual | — | 2026-08-11 |
| BTAI | BioXcel Therapeutics Inc | $25M | Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar DisorderNCT05025605Absolute change from baseline in the Positive and Negative Syndrome Scale - Excited Component (PEC) total score | Phase 1 | Recruiting | Drug: BXCL501 80 Micrograms, Placebo Film, BXCL501 120 Micrograms, BXCL501 60 Micrograms | Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I, Bipolar Disorder II | 140 | 2021-08-27 | 2027-07-31 | in 345 d | 2026-08-11 |
| BTAI | BioXcel Therapeutics Inc | $25M | Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar DisorderNCT06041646results2026-01-02Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score | Phase 4 | Completed | Drug: Sublingual film containing Igalmi | Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder, Schizophreniform Disorders | 29 | 2023-10-02 | 2024-04-29actual | — | 2026-08-11 |
| RAPP | Rapport Therapeutics Inc. | $2.4B | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I DisorderNCT07046494Young Mania Rating Scale (YMRS) | Phase 2 | Active, not recruiting | Drug: RAP-219 · Other: Placebo | Bipolar 1 Disorder | 253 | 2025-07-25 | 2026-08-05actual | — | 2026-08-10 |
| BTAI | BioXcel Therapeutics Inc | $25M | Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)NCT05658510Part 1: Change from baseline in Positive and Negative Syndrome Scale - Excited (PEC) total score | Phase 3 | Completed | Drug: BXCL501, Matching Placebo | Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders | 452 | 2022-11-21 | 2025-08-15actual | — | 2026-08-07 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar DisorderNCT07071532Maximum Plasma Concentration (Cmax) of ABBV-932 and active metabolites DCAR and DDCAR | Phase 1 | Not yet recruiting | Drug: ABBV-932, Itraconazole | Bipolar Disorder | 20 | 2026-08-21 | Feb 2027 | ≤ 192 d | 2026-08-06 |
| BTAI | BioXcel Therapeutics Inc | $25M | Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar DisorderNCT07116694Informant and Clinician ratings comparison | Phase 2 | Completed | Drug: BXCL501 Sublingual Film | Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Psychomotor Agitation | 33 | 2025-06-19 | 2025-10-07actual | — | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)NCT07286175Time to Relapse Defined as Days from Randomization to the Date on Which the Participant Meets Any Relapse Criterion | Phase 2 | Recruiting | Drug: Brenipatide, Placebo | Bipolar Disorder | 400 | 2025-11-24 | Nov 2027 | ≤ 467 d | 2026-08-06 |
| ALKS | Alkermes, Inc. | $8.3B | An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315)NCT07744113expanded access | — | Available | Drug: OLZ/SAM | Bipolar 1 Disorder, Schizophrenia Disorder | — | — | — | — | 2026-08-04 |
| NBIX | Neurocrine Biosciences | $15.7B | An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current ManiaNCT07288320Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Day 21 | Phase 2 | Recruiting | Drug: NBI-1117568, Placebo | Bipolar I Disorder, Mania | 150 | 2025-12-24 | Feb 2028 | ≤ 558 d | 2026-07-31 |
| ALZN | Alzamend Neuro, Inc. | $8M | A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I DisorderNCT07540338To evaluate differences in brain and/or brain structure lithium PK relative to plasma PK for AL001 capsule compared to a lithium carbonate capsule. | Phase 1/2 | Recruiting | Drug: AL001, Lithium carbonate | Bipolar I Disorder | 20 | 2026-05-11 | Dec 2026 | ≤ 133 d | 2026-07-28 |
| ABBV | AbbVie | $457.5B | A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.NCT04777357Number of Participants with Adverse Events | Phase 3 | Recruiting | Drug: Cariprazine, Placebo | Depression, Bipolar I Disorder | 380 | 2021-04-28 | Mar 2027 | ≤ 223 d | 2026-07-27 |
| LBRX | LB Pharmaceuticals Inc. | $1.5B | Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.NCT07494305Change From Baseline in Montgomery Åsberg Depression Rating -10 core symptom scale (MADRS-10) | Phase 2 | Recruiting | Drug: LB-102 · Other: Placebo | Bipolar I Disorder | 320 | 2026-01-23 | Feb 2028 | ≤ 558 d | 2026-07-27 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or LamotrigineNCT07140913Change from baseline in Young Mania Rating Scale (YMRS) at Week 5 | Phase 3 | Recruiting | Drug: Xanomeline/Trospium Chloride, Placebo | Mania, Bipolar Disorder | 424 | 2025-10-08 | 2027-06-28 | in 312 d | 2026-06-23 |
| NBIX | Neurocrine Biosciences | $15.7B | A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) InhibitorNCT07105111Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score (AIMS 1-7) at Week 24 | Phase 4 | Recruiting | Drug: Valbenazine | Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia | 50 | 2025-08-29 | Jan 2027 | ≤ 164 d | 2026-06-16 |
| XENE | Xenon Pharmaceuticals Inc. | $6.1B | A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)NCT07172516Change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6. | Phase 3 | Recruiting | Drug: Azetukalner, Placebo | Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder | 400 | 2025-08-08 | Jun 2028 | ≤ 680 d | 2026-06-03 |
| XENE | Xenon Pharmaceuticals Inc. | $6.1B | An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)NCT07217860Severity and frequency of treatment-emergent adverse events, serious adverse events, adverse events of special interest, and events of clinical interest | Phase 3 | Enrolling by invitation | Drug: Azetukalner | Bipolar Depression, Bipolar I Disorder, Bipolar Disorder, Bipolar II Disorder | 400 | 2025-10-30 | Jun 2029 | ≤ 1,045 d | 2026-06-03 |
| ABBV | AbbVie | $457.5B | Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I DisorderNCT06256367observationalChange From Baseline on Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | — | Completed | — | Bipolar I Disorder | 120 | 2024-04-18 | 2026-01-23actual | — | 2026-02-24 |
| NBIX | Neurocrine Biosciences | $15.7B | Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive DyskinesiaNCT05859698results2026-01-16Change From Baseline in the Tardive Dyskinesia Impact Scale (TDIS) Total Score at Week 24 | Phase 4 | Completed | Drug: Valbenazine | Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia | 59 | 2023-05-09 | 2024-12-27actual | — | 2026-01-16 |
| ABBV | AbbVie | $457.5B | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II DisorderNCT06605599Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | Phase 2 | Completed | Drug: ABBV-932, Placebo for ABBV-932 | Bipolar I Disorder, Bipolar II Disorder | 161 | 2024-10-15 | 2025-11-12actual | — | 2026-01-12 |
| ABBV | AbbVie | $457.5B | Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum DisorderNCT04578756Number of Participants With Treatment-emergent Adverse Events (TEAEs) in the Treatment Period | Phase 3 | Completed | Drug: Cariprazine Flexible Dose, Cariprazine Flexible Dose | Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD) | 310 | 2021-02-01 | 2025-10-06actual | — | 2025-10-27 |
| VNDA | Vanda Pharmaceuticals | $329M | Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State ConditionsNCT06494397Bioequivalence between VHX-896 tablets relative to iloperidone tablets | Phase 1 | Completed | Drug: VHX-896 and iloperidone, Iloperidone and VHX-896 | Schizophrenia, Bipolar I Disorder | 26 | 2024-07-11 | 2024-10-24actual | — | 2025-09-19 |
| VNDA | Vanda Pharmaceuticals | $329M | Safety and Tolerability of Open-Labeled Iloperidone in AdolescentsNCT05648591Number of participants with treatment-emergent adverse events (TEAEs) in the treatment period. | Phase 4 | Recruiting | Drug: Iloperidone | Schizophrenia, Bipolar I Disorder | 100 | 2023-05-24 | 2026-03-31 | — | 2025-03-04 |
| 4503.T | Astellas Pharma Inc | $26.0B | Long-term Study of FK949E in Elderly Bipolar Disorder PatientsNCT01737268results2017-10-31Change From Baseline to Last Assessment in Treatment Period in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | Phase 3 | Completed | Drug: FK949E | Bipolar Disorder, Elderly | 20 | 2012-10-29 | 2016-06-29actual | — | 2024-11-19 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive EpisodesNCT01725308results2017-02-08Change From Baseline to End of Treatment Period I in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | Phase 2/3 | Completed | Drug: FK949E, Placebo | Bipolar Disorder | 431 | 2012-02-07 | 2015-08-01actual | — | 2024-11-15 |
| 4503.T | Astellas Pharma Inc | $26.0B | Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive EpisodesNCT02362412results2017-03-17Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | Phase 3 | Completed | Drug: FK949E | Bipolar Depression | 22 | 2015-02-18 | 2016-02-06actual | — | 2024-11-15 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar DisorderNCT03403790observationalSafety assessed by incidence of serious adverse events | — | Completed | Drug: Quetiapine | Depression, Bipolar Disorder | 369 | 2018-01-15 | 2020-03-19actual | — | 2024-10-16 |
| ALKS | Alkermes, Inc. | $8.3B | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831NCT03201757results2024-09-26Incidence of Adverse Events | Phase 3 | Completed | Drug: ALKS 3831 | Schizophrenia, Schizophreniform Disorder, Bipolar I Disorder | 523 | 2017-06-15 | 2023-09-06actual | — | 2024-09-26 |
| ABBV | AbbVie | $457.5B | Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World SettingNCT05956483observationalPositive Predictive Value (PPV) of Rapid Mood Screener (RMS) | — | Completed | — | Bipolar I Disorder | 423 | 2023-12-04 | 2024-08-16actual | — | 2024-08-20 |
| OGN | Organon and Co | $3.6B | 9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)NCT00143182Maintenance of the effect (Asenapine comparable to olanzapine in terms of the reduction of symptoms achieved in the short term (ie. 3 week studies [A7501004 or A7501005]) as measured on the Young Mania Rating Scale | Phase 3 | Completed | Drug: Asenapine, Olanzapine | Bipolar Disorder | 504 | 2005-01-07 | 2006-06-28actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | 3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)NCT00159744Changes in bipolar manic or mixed symptoms reflected in the scores on the YMRS (Young Mania Rating Scale) | Phase 3 | Completed | Drug: Asenapine, Olanzapine, Placebo | Bipolar Disorder | 488 | 2004-11-30 | 2006-04-29actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)NCT00159796Change from Baseline to Day 21 on the Young Mania Rating Scale (YMRS) Total Score | Phase 3 | Completed | Drug: Asenapine, Olanzapine, Placebo | Bipolar Disorder | 489 | 2004-12-14 | 2006-03-28actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)NCT00764478results2015-04-24Change From Baseline in Young Mania Rating Scale (Y-MRS) Total Score at Day 21 | Phase 3 | Completed | Drug: Asenapine, Asenapine, Placebo | Bipolar 1 Disorder | 367 | 2012-04-06 | 2014-04-30actual | — | 2024-06-18 |
| OGN | Organon and Co | $3.6B | A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)NCT01206517results2012-12-21Maximum Plasma Concentration (Cmax) of Asenapine | Phase 1 | Completed | Drug: Asenapine 2.5 mg, Asenapine 5 mg, Asenapine 10 mg | Schizophrenia, Bipolar I Disorder | 30 | 2010-07-18 | 2011-08-04actual | — | 2024-05-23 |
| OGN | Organon and Co | $3.6B | Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898)NCT01349907results2015-03-09Number of Participants Who Experienced Clinical or Laboratory Adverse Events | Phase 3 | Completed | Drug: Asenapine, Rescue medication | Bipolar Disorder | 322 | 2011-06-16 | 2014-09-05actual | — | 2024-05-22 |
| OGN | Organon and Co | $3.6B | 12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)NCT00145470results2019-09-16Least Squares Mean Change From Baseline in Young-Mania Rating Scale (Y-MRS) Score at Day 21 | Phase 3 | Completed | Drug: Asenapine, Placebo | Bipolar Disorder | 326 | 2005-06-02 | 2007-02-28actual | — | 2024-05-21 |
| VNDA | Vanda Pharmaceuticals | $329M | Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I DisorderNCT04819776results2024-04-16Change From Baseline to Week 4 in Young Mania Rating Scale (YMRS) Total Score | Phase 3 | Completed | Drug: Iloperidone, Iloperidone Placebo | Bipolar I Disorder | 417 | 2021-03-22 | 2022-09-07actual | — | 2024-04-18 |
| NVS | Novartis | — | The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.NCT00154323Duration of remission | Phase 4 | Completed | Drug: Oxcarbazepine | Bipolar Disorder | 55 | Jan 2003 | Jan 2006actual | — | 2023-12-14 |
| BIIB | Biogen | $31.4B | A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive EpisodeNCT03692910results2022-04-20Part A: Number of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) | Phase 2 | Completed | Drug: SAGE-217, Placebo | Bipolar Disorder I, Bipolar Disorder II, Major Depressive Episode | 35 | 2018-08-23 | 2019-05-21actual | — | 2023-12-13 |
| ALKS | Alkermes, Inc. | $8.3B | Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I DisorderNCT04987658Maximum plasma concentration observed | Phase 1 | Completed | Drug: OLZ/SAM | Bipolar I Disorder | 7 | 2021-07-22 | 2023-08-11actual | — | 2023-11-22 |
| ABBV | AbbVie | $457.5B | A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed FeaturesNCT03573297results2023-09-28Time to First Relapse of Any Mood Episode During the Double-Blind Treatment Period | Phase 3 | Completed | Drug: Cariprazine, Placebo | Bipolar I Disorder, Mania, Depression | 901 | 2018-06-15 | 2022-09-05actual | — | 2023-09-28 |
| ALKS | Alkermes, Inc. | $8.3B | Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I DisorderNCT03187769results2023-01-19Percent Change From Baseline in Body Weight at Week 12 | Phase 3 | Completed | Drug: ALKS 3831, Olanzapine | Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder | 426 | 2017-06-08 | 2021-12-01actual | — | 2023-01-19 |
| OGN | Organon and Co | $3.6B | 40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)NCT00159783results2010-07-16Participants Who Experienced Adverse Event(s) | Phase 3 | Completed | Drug: asenapine, Olanzapine | Bipolar Disorder | 218 | Jul 2005 | Apr 2007actual | — | 2022-02-09 |
| OGN | Organon and Co | $3.6B | 40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)NCT00145509results2010-04-16Number of Participants Who Experienced an Adverse Event | Phase 3 | Completed | Drug: Asenapine, Placebo | Bipolar Disorder | 77 | Aug 2005 | Dec 2007actual | — | 2022-02-08 |
| OGN | Organon and Co | $3.6B | Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307)NCT01495741observationalNumber of Participants with Bipolar Disorder with Identified and Potential Clinically Important Risks | — | Completed | — | Bipolar Disorder, Schizophrenia | 42 | 2013-07-01 | 2017-12-18actual | — | 2022-02-04 |
| OGN | Organon and Co | $3.6B | An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)NCT01498770observationalFrequency and Proportion of Use, by Psychiatric Diagnosis, Among Asenapine and Aripiprazole Participants Aged 18 or Greater | — | Completed | Drug: Asenapine, Aripiprazole, Quetiapine, Risperidone, Olanzapine, Ziprasidone, Iloperidone, Paliperidone, Lurasidone, Clozapine, Amisulpride, Sertindole, Zotepine | Bipolar Disorder | 42 | 2013-04-01 | 2017-12-21actual | — | 2022-02-04 |
| BWAY | Brainsway | — | Safety and Efficacy Study of Deep Transcranial Magnetic Stimulation in Bipolar DepressionNCT01566591HDRS-21 Score measured by change from baseline. | Not applicable | Unknown status | Device: Deep TMS Treatment, Sham Treatment | Bipolar Depression | 120 | May 2012 | Dec 2021 | — | 2021-02-04 |
| VNDA | Vanda Pharmaceuticals | $329M | Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or SchizophreniaNCT04127058The frequency of treatment-emergent adverse events as measured by the number of events | Phase 1 | Completed | Drug: Iloperidone | Bipolar I Disorder, Schizophrenia | 12 | 2019-10-07 | 2019-11-27actual | — | 2020-04-13 |
| AZN | AstraZeneca | — | Predictors of Recurrence in Bipolar Disorder in SpainNCT00690859observationalOnset of mood disorders episodes (depression, mania, hypomania and mixed) during the 1 year follow-up period | — | Completed | — | Bipolar Disorder | 595 | Jun 2007 | Mar 2009actual | — | 2020-01-22 |
| OPK | OPKO Health, Inc. | $1.0B | Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I DisorderNCT01674010results2015-10-12Treatment Emergent Adverse Events | Phase 2 | Terminatedsponsor's stated reason: Business Decision | Drug: ELND005, Lamotrigine, Valproic acid, Placebo | Bipolar 1 Disorder | 309 | Aug 2012 | Jun 2014actual | — | 2019-10-21 |
| BIIB | Biogen | $31.4B | Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.NCT00908154Safety and tolerability will be evaluated by monitoring AEs and concomitant medication, ECG, Lead II monitoring, Holter monitoring, vital signs, and laboratory parameters. | Phase 1 | Completed | Drug: Placebo, GSK1014802 | Bipolar Depression, Bipolar Disorder | 51 | 2008-05-31 | 2008-12-31actual | — | 2017-10-30 |
| BIIB | Biogen | $31.4B | GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy VolunteersNCT00488566Part1:AEs for the duration of the study; | Phase 1 | Completed | Drug: GSK drug · Other: Placebo, Lamictal | Bipolar Disorder | 50 | 2007-05-31 | 2008-05-31actual | — | 2017-10-26 |
| NVS | Novartis | — | Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I DisorderNCT00139594Safety and tolerability of treatment with licarbazepine over 52 weeks. | Phase 4 | Completed | Drug: licarbazepine | Bipolar Disorder | 181 | Dec 2004 | Jul 2007actual | — | 2017-03-28 |
| NVS | Novartis | — | An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I DisorderNCT00238485Safety and tolerability of licarbazepine with respect to adverse events, serious adverse events, changes in laboratory values, ECGs and vital signs. | Phase 3 | Completed | Drug: Licarbazepine | Bipolar I Disorder | 251 | Jan 2005 | Jul 2007actual | — | 2017-03-28 |
| NVS | Novartis | — | An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.NCT00228059Safety and tolerability of licarbazepine with respect to adverse events, serious adverse events, changes in laboratory values, ECGs and vital signs. | Phase 3 | Completed | Drug: Licarbazepine | Bipolar I Disorder | 132 | Jan 2005 | Jul 2007actual | — | 2017-02-23 |
| AZN | AstraZeneca | — | Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar DepressionNCT01256177results2016-02-03Change From Baseline (Visit 2) to End of Study (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | Phase 3 | Completed | Drug: Quetiapine Fumarate (SEROQUEL) Extended Release, Placebo | Bipolar Depression | 361 | Dec 2010 | Nov 2012actual | — | 2016-04-15 |
| AZN | AstraZeneca | — | Observation Study of the Clinical Management of Bipolar DisorderNCT01770704observationalNumber of episodes (depression, mania, hypomania or mixed). | — | Completed | — | Bipolar Disorder | 520 | Feb 2013 | Jul 2014actual | — | 2016-04-07 |
| AZN | AstraZeneca | — | Evaluation of Sub-syndromal Symptoms After Acute Depressive Episode in Bipolar DisorderNCT01663974observationalThe prevalence of sub-syndromal symptoms after an acute depressive episode in Bipolar Disorder patients, as measured by scoring on YMRS and MADRS scales and MVAS-BP self-administered questionnaire. | — | Terminated | — | Bipolar Disorder, Sub-syndromal Symptoms | 125 | Apr 2013 | Dec 2013actual | — | 2015-03-09 |
| LLY | Eli Lilly and Company | $1.15T | Study in Adolescents With Schizophrenia or Bipolar DisorderNCT00982020results2014-12-17Mean Change From Baseline to 52 Weeks in Body Mass Index (BMI) for All Participants | Phase 4 | Completed | Drug: Olanzapine · Behavioral: Standard behavioral weight intervention, Intense behavioral weight intervention | Bipolar I Disorder, Schizophrenia | 203 | Sep 2009 | May 2013actual | — | 2014-12-17 |
| AZN | AstraZeneca | — | An Epidemiological Registry Study to Evaluate Clinical Practice Treatment in Patients With Bipolar DisorderNCT01455961observationalDescription of detailed clinical treatment in terms of duration of treatment, doses, drug switches, and add-on therapy, in patients with BD and on treatment with quetiapine XR and/or quetiapine IR before, at and after the index date. | — | Completed | — | Bipolar Disorder | 16,000 | Nov 2011 | Apr 2012actual | — | 2014-08-21 |
| AZN | AstraZeneca | — | Pediatric Bipolar DepressionNCT00811473results2011-12-01Change in the Children Depression Rating Scale, Revised (CDRS-R) Total Score From Baseline to Final Assessment (Day 57) | Phase 3 | Completed | Drug: Quetiapine XR, Placebo | Bipolar Depression | 193 | Jan 2009 | Nov 2010actual | — | 2014-07-15 |
| HLUN-B.CO | H. Lundbeck A/S | — | Efficacy and Safety of Lu AA39959 in Patients With Bipolar DepressionNCT00771134Depressive symptoms as measured by the change from baseline in total MADRS score | Phase 2 | Terminatedsponsor's stated reason: Study was previously suspended and is now terminated | Drug: Lu AA39959, Placebo, Quetiapine | Bipolar Disorder | 105 | Dec 2008 | Jun 2009actual | — | 2014-05-28 |
| AZN | AstraZeneca | — | A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative,StudyNCT01254721results2014-05-08The Changes From Baseline in Young Mania Rating Scale (YMRS) Total Score to Day 29 | Phase 4 | Terminatedsponsor's stated reason: Difficulty of recruitment. | Drug: Quetiapine fumarate, lithium | Acute Bipolar Mania | 131 | Dec 2010 | Oct 2012actual | — | 2014-05-08 |
| AZN | AstraZeneca | — | General Practice Research Database Seroquel XR Safety StudyNCT01447082observationalThe outcome of interest will be evaluated by means of relative risk based on incidence rates estimates in users of quetiapine XR vs corresponding incidence rates in users of comparison drugs | — | Completed | — | Schizophrenia, Major Depressive Disorder, Bipolar Disorder | 37,372 | Oct 2008 | Dec 2012actual | — | 2014-02-07 |
| AZN | AstraZeneca | — | EMR Data to Assess Monitoring of Patients Treated With QuetiapineNCT01793324observationalDetermination whether physicians in the UK and Germany perform monitoring of patients treated with Seroquel® and Seroquel® XR including measurement of the following during patient encounters: weight at drug initiation and over the course of treatment. | — | Completed | — | Schizophrenia, Bipolar Disorder, Major Depressive Disorder | 6,153 | Apr 2012 | Jun 2013actual | — | 2014-01-28 |
| AZN | AstraZeneca | — | Physician Survey on Monitoring of Patients Treated With QuetiapineNCT01795326observationalDetermination via survey whether physicians or someone in their practice perform monitoring of patients treated with Seroquel or Seroquel XR for metabolic issues related to treatment; refer their patients to another physician for monitoring. | — | Completed | — | Schizophrenia, Bipolar Disorder, Major Depressive Disorder | 800 | Jun 2013 | Sep 2013actual | — | 2014-01-28 |
| LLY | Eli Lilly and Company | $1.15T | A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar DepressionNCT00844857results2013-02-18Change From Baseline in the Children's Depression Rating Scale Revised (CDRS-R) Total Score at Week 8 | Phase 4 | Completed | Drug: Olanzapine Fluoxetine Combination (OFC), Placebo | Bipolar Depression | 291 | Apr 2009 | Feb 2012actual | — | 2013-02-18 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Evaluating Bifeprunox in Bipolar DepressionNCT00134459The objective of this study is to investigate if 8 weeks of treatment with flexible doses of bifeprunox (20 to 40 mg/day) is superior to treatment with placebo in depressed outpatients with bipolar disorder. | Phase 3 | Completed | Drug: Bifeprunox, Placebo | Bipolar Disorder | 434 | Jun 2005 | May 2006actual | — | 2013-02-15 |
| AZN | AstraZeneca | — | Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic PatientsNCT00139074The number of responders in the two treatment groups (quetiapine + sodium valproate placebo/quetiapine + sodium valproate) | Phase 4 | Terminatedsponsor's stated reason: terminated due to very low recruitment rate (27 June 2006) | Drug: Quetiapine fumarate, sodium valproate | Bipolar Disorder | 17 | Jul 2005 | Jun 2006actual | — | 2013-01-28 |
| AZN | AstraZeneca | — | Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I DisorderNCT00227305results2012-10-05Incidence and Nature of Adverse Events (AEs) | Phase 3 | Completed | Drug: quetiapine fumarate | Schizophrenia, Bipolar I Disorder | 381 | Aug 2004 | Dec 2007actual | — | 2013-01-08 |
| AZN | AstraZeneca | — | Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar DepressionNCT00083954Change from baseline to week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score | Phase 3 | Completed | Drug: Quetiapine Fumarate | Bipolar Disorder | 530 | Jun 2004 | — | — | 2013-01-04 |
| AZN | AstraZeneca | — | Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I ManiaNCT00090311Compare efficacy of Quetiapine with placebo in the treatment of bipolar I mania as assessed by the YMRS total score, change from baseline to Day 21 | Phase 3 | Completed | Drug: quetiapine fumarate | Bipolar Disorder | 220 | Jul 2004 | — | — | 2013-01-04 |
| AZN | AstraZeneca | — | Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar DisorderNCT00114686Change in the proportion of heavy drinking days from Baseline to Week 12, as derived from the Timeline Followback (TLFB) scale | Phase 3 | Completed | Drug: Quetiapine fumarate, lithium, divalproex | Bipolar I Disorder, Alcohol Dependence | 350 | Jan 2006 | — | — | 2013-01-04 |
| AZN | AstraZeneca | — | Seroquel in Bipolar Depression Versus SSRINCT00119652Change from baseline to Week 8 assessment in the total score on the Montgomery-Asberg Depression Rating Scale (MADRS) | Phase 3 | Completed | Drug: quetiapine fumarate (Seroquel), paroxetine · Behavioral: mood stabilizing activity | Bipolar Disorder, Bipolar Depression, Depression | 676 | May 2005 | — | — | 2013-01-04 |
| AZN | AstraZeneca | — | Seroquel in Bipolar Depression Versus LithiumNCT00206141The change from randomization to Week 8 assessment in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. | Phase 3 | Completed | Drug: Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood) | Bipolar Disorder, Bipolar Depression, Depression | 672 | Aug 2005 | — | — | 2013-01-04 |
| AZN | AstraZeneca | — | Functional Assessment of Patients With Acute Bipolar Depression After 8 Months of Follow-upNCT01255982observationalDifference between basal and final Functional Assessment Staging (FAST) score to evaluate the functional change | — | Completed | — | Bipolar Disorder, Bipolar Depression | 249 | Mar 2011 | Dec 2011actual | — | 2012-10-26 |
| AZN | AstraZeneca | — | IBIS: Italian Burden of Illness on Schizophrenia & Bipolar DisorderNCT01392482observationalDescribe the pharmacoutilization of antipsychotics treatment (including typical and atypical) for patients affected by schizophrenia and bipolar disorder in order to evaluate the level of treatment variability for these patients | — | Completed | — | Schizophrenia, Bipolar Disorder | 751,725 | Jul 2011 | Sep 2012actual | — | 2012-09-17 |
| AZN | AstraZeneca | — | Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.NCT00521365results2012-07-17Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to End of Treatment (Day 21) | Phase 4 | Completed | Drug: Quetiapine 600mg | Bipolar Disorder, Bipolar Affective Psychosis, Mania, Manic Disorder, Manic State | 88 | May 2008 | Aug 2009actual | — | 2012-07-17 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY2979165 in Healthy SubjectsNCT01383967Number of participants with clinically significant effects | Phase 1 | Completed | Drug: LY2979165, placebo | Bipolar Disorder | 102 | Jul 2011 | Jun 2012actual | — | 2012-06-14 |
| AZN | AstraZeneca | — | Study of the Clinical Management of Bipolar DiseaseNCT01062607observationalDemographic variables | — | Completed | — | Bipolar Disorders | 2,965 | Apr 2010 | Jun 2011actual | — | 2012-05-23 |
| AZN | AstraZeneca | — | Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on TherapyNCT00857584results2012-04-10The Mean Change From Baseline to Week 2 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score | Phase 3 | Completed | Drug: Extended release quetiapine (quetiapine XR), Sertraline, adequate mood stabilizer | Bipolar Disorder, Bipolar Depression | 27 | May 2009 | Feb 2011actual | — | 2012-04-18 |
| AZN | AstraZeneca | — | Study of the Broad Clinical Benefit for Seroquel XR With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current TherapyNCT01128114results2012-04-10The Proportion of Patients With Improvement From Baseline to Week 4 in Clinical Global Impression-Clinical Benefit Score (LOCF) | Phase 4 | Terminatedsponsor's stated reason: Poor recruitment | Drug: Quetiapine fumarate (Seroquel XR) | Acute Bipolar Mania | 32 | Jun 2010 | Mar 2011actual | — | 2012-04-17 |
| AZN | AstraZeneca | — | A Study Evaluating the Efficacy of Administered Maintenance Treatments in Bipolar Disorder I and II.NCT01202604observationalThe proportion of patients (n, %) who will experience a relapse episode (manic, hypomanic, depressive, mixed) | — | Completed | — | Bipolar Disorder | 294 | Sep 2010 | Dec 2011actual | — | 2011-12-20 |
| AZN | AstraZeneca | — | PHARMO Institute Seroquel Safety StudyNCT01342120observationalThe outcomes of interest will be evaluated by means of relative risk based on incidence rates estimates in users of quetiapine vs corresponding incidence rates in users of comparison drugs | — | Completed | — | Schizophrenia, Major Depressive Disorder, Bipolar Disorder, Generalized Anxiety Disorder | 18,325 | Sep 2010 | Nov 2010actual | — | 2011-09-02 |
| AZN | AstraZeneca | — | Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451NCT01196676To assess the safety and tolerability of single ascending oral doses of AZD4451 by assessing AEs, vital signs, physical examinations, neurological examinations clinical laboratory parameters, Columbia Suicide Severity Rating Scale(CSSRS), EEGs and ECGs | Phase 1 | Completed | Drug: AZD4451, Placebo | Bipolar Disorder | 63 | Aug 2010 | Apr 2011actual | — | 2011-08-01 |
| LLY | Eli Lilly and Company | $1.15T | Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, DepressedNCT00618748results2011-06-27Percentage of Participants With Adverse Events Leading to Discontinuation | Phase 3 | Completed | Drug: Olanzapine | Bipolar I Disorder | 101 | Feb 2008 | Sep 2010actual | — | 2011-07-27 |
| AZN | AstraZeneca | — | The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription BehavioursNCT01377896observational | — | Completed | — | Schizophrenia, Bipolar Disorders, Major Depressive Disorders | 221 | Jul 2010 | Oct 2010actual | — | 2011-06-28 |
| LLY | Eli Lilly and Company | $1.15T | A First Human Dose Study to Investigate Safety and Tolerability of LY2979165 in Healthy VolunteersNCT01248052Number of participants with clinically significant effects | Phase 1 | Completed | Drug: LY2979165, Placebo | Bipolar Disorder | 25 | Nov 2010 | May 2011actual | — | 2011-06-27 |
| LLY | Eli Lilly and Company | $1.15T | Olanzapine Treatment of Patients With Bipolar I DisorderNCT00510146results2011-05-26Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score (Acute Phase) | Phase 3 | Completed | Drug: Olanzapine, Placebo | Depression, Bipolar | 514 | Aug 2007 | Mar 2010actual | — | 2011-05-26 |
| AZN | AstraZeneca | — | Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar DepressionNCT00926393results2011-03-31Modified Bond-Lader Visual Analog Scale Score After 50-mg Dose (Day 2) | Phase 4 | Completed | Drug: Quetiapine Immediate Release, Quetiapine Extended Release | Bipolar Depression | 139 | Jun 2009 | Aug 2009actual | — | 2011-05-11 |
| AZN | AstraZeneca | — | Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar DepressionNCT00060489 | Phase 3 | Completed | Drug: SEROQUEL (quetiapine fumarate) Tablets | Bipolar Disorder, Depression, Bipolar | — | Sep 2002 | Sep 2003actual | — | 2011-01-26 |
| SNY | Sanofi | — | Safety Study of Sodium Divalproate in Bipolar Disorder in AdolescentsNCT00271258clinical examination | Phase 3 | Completed | Drug: SODIUM DIVALPROATE | Bipolar Disorder | 200 | Jan 2005 | — | — | 2011-01-11 |
| LLY | Eli Lilly and Company | $1.15T | Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I DisorderNCT00129220results2010-02-15Change From Baseline to 3 Week Endpoint in Young Mania Rating Scale (YMRS) Total Score | Phase 3 | Completed | Drug: olanzapine, haloperidol, placebo | Bipolar Disorder | 224 | Jul 2005 | Jan 2009actual | — | 2010-12-28 |
| AZN | AstraZeneca | — | A NIS Evaluating the Treatment Patterns of Atypical Antipsychotics in Patients Diagnosed With Bipolar I or II DisorderNCT00888264observationalDetails of any AAP prescribed 1 to 6 months prior to the first study visit: | — | Completed | — | Bipolar Disorders | 152 | May 2009 | Aug 2010actual | — | 2010-12-22 |
| AZN | AstraZeneca | — | FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute PsychosisNCT00486798Assessment of Positive and Negative Syndrome Scale-Excitatory Subscale (PANSS-EC) at day 5 compared with baseline at day 1 | Phase 3 | Terminatedsponsor's stated reason: study was not ethically acceptable to continue and therefore it was finally stopped | Drug: Quetiapine · Procedure: Rating Scales, Self Assessment Form, Blood and urine samples, Sleeping pattern | Psychotic Disorders, Schizophrenia, Bipolar Disorder | — | May 2007 | Aug 2007actual | — | 2010-12-10 |
| AZN | AstraZeneca | — | Spanish Validation of Tool Questionnaire to Assess Patients´Perception About Antipsychotic TreatmentNCT00692133observationalTOOL questionnaire | — | Completed | — | Schizophrenia, Bipolar Disorder | 250 | Mar 2008 | Aug 2008actual | — | 2010-12-10 |
| AZN | AstraZeneca | — | Efficacy and Safety of Seroquel and Lithium as Monotherapy in Acute Mania Treatment in Bipolar Disorder PatientsNCT00448578Effectiveness of quetiapine fumarate used as monotherapy in treatment of symptoms of acute mania in patients with bipolar disorder by evaluation of the change from baseline in YMRS total score at Day 28 using the last observation carried forward method | Phase 3 | Completed | Drug: Quetiapine Fumarate, Lithium | Mania, Bipolar Disorder | 150 | Aug 2005 | — | — | 2010-12-09 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Bipolar Disorder is matched — 11 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Bipolar Disorder
- Bipolar I Disorder
- Bipolar Depression
- Bipolar II Disorder
- Bipolar 1 Disorder
- Depression, Bipolar
- Bipolar Disorders
- Acute Bipolar Mania
- Affective Psychosis, Bipolar
- Bipolar Disorder I
- Bipolar Disorder II
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Bipolar Disorder” (a text search, wider than this page)